Catechol-O-methyltransferase Val158Met polymorphism is associated with somatosensory amplification and nocebo responses.
A large number of unwanted adverse events and symptoms reported by patients in clinical trials are not caused by the drug provided, since most of adverse events also occur in corresponding placebo groups. These nocebo effects also play a major role in drug discontinuation in clinical practice, negat...
Үндсэн зохиолчид: | Laura Wendt, Antje Albring, Sven Benson, Harald Engler, Andrea Engler, Anke Hinney, Winfried Rief, Oliver Witzke, Manfred Schedlowski |
---|---|
Формат: | Өгүүллэг |
Хэл сонгох: | English |
Хэвлэсэн: |
Public Library of Science (PLoS)
2014-01-01
|
Цуврал: | PLoS ONE |
Онлайн хандалт: | http://europepmc.org/articles/PMC4164653?pdf=render |
Ижил төстэй зүйлс
Ижил төстэй зүйлс
-
Catechol-o-methyltransferase, cognition, and psychosis: Val158Met and beyond.
-н: Tunbridge, E, зэрэг
Хэвлэсэн: (2006) -
VAL158MET catechol O-methyltransferase polymorphism contributes to the development of preeclampsia
-н: Tamara Sljivancanin Jakovljevic, зэрэг
Хэвлэсэн: (2020-10-01) -
Subjective reward processing and catechol-O- methyltransferase Val158Met polymorphism as potential research domain criteria in addiction: A pilot study
-н: Nico Rohlfing, зэрэг
Хэвлэсэн: (2022-10-01) -
Human plasma homocysteine levels are associated with the catechol-O-methyltransferase Val158Met polymorphism
-н: Tunbridge, E, зэрэг
Хэвлэсэн: (2007) -
Association between the Catechol O-methyltransferase (COMT) Val158met polymorphism and different dimensions of impulsivity.
-н: Leandro Fernandes Malloy-Diniz, зэрэг
Хэвлэсэн: (2013-01-01)